Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.
IMPORTANCE Standard molecularly based strategies to predict and/or prevent oral cancer development in patients with oral premalignant lesions (OPLs) are lacking. OBJECTIVE To test if the epidermal growth factor receptor inhibitor erlotinib would reduce oral cancer development in patients with high risk OPLs defined by specific loss of heterozygosity (LOH) profiles. Secondary objectives included prospective determination of LOH as a prognostic marker in OPLs. DESIGN The Erlotinib Prevention of Oral Cancer (EPOC) study was a randomized, placebo controlled, double bind trial. Accrual occurred from November 2006 through July 2012, with a median follow up time of 35 months in an ambulatory care setting in 5 US academic referral institutions. Patients with OPLs were enrolled in the protocol, and each underwent LOH profiling (N 379) they were classified as high risk (LOH positive) or low risk (LOH negative) patients based on their LOH profiles and oral cancer history. The randomized sample consisted of 150 LOH positive patients. INTERVENTIONS Oral erlotinib treatment (150 mg/d) or placebo for 12 months. MAIN OUTCOMES AND MEASURES Oral cancer free survival (CFS) RESULTS A total of 395 participants were classified with LOH profiles, and 254 were classified LOH positive. Of these, 150 (59% were randomized, 75 each to the placebo and erlotinib groups. The 3 year CFS rates in placebo and erlotinib treated patients were 74% and 70% respectively (hazard ratio [HR] 1.27; 95% CI, 0.68 2.38; P .45) The 3 year CFS was significantly lower for LOH positive compared with LOH negative groups (74% vs 87% HR, 2.19; 95% CI, 1.25 3.83; P .01) Increased EGFR gene copy number correlated with LOH positive status (P .001) and lower CFS (P .01) The EGFR gene copy number was not predictive of erlotinib efficacy. Erlotinib induced skin rash was associated with improved CFS (P .01) CONCLUSIONS AND RELEVANCE In this trial, LOH was validated as a marker of oral cancer risk and found to be associated with increased EGFR copy number (the target of the intervention) Erlotinib did not, however, improve CFS in high risk patients with LOH positive or high EGFR gene copy number OPLs. These results support incorporation of LOH testing as a prognostic tool in routine clinical practice but do not support erlotinib use in this setting. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00402779.
JAMA oncology